This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk05: Greetings and welcome to the VaxArt business update in second quarter 2023 financial results conference call. A question and answer session will follow management's opening remarks. Individual investors may submit written questions to ir at vaxart.com. As a reminder, this conference is being recorded. I would now like to turn the webcast over to your host, Brandt Bann, Senior Vice President and Business Operations. Thank you. You may begin.
spk06: Good afternoon and welcome to today's call. Joining us from VaxArt are Andre Florio, our Chief Executive Officer, Dr. Sean Tucker, our Founder and Chief Scientific Officer, Dr. James Cummings, our Chief Medical Officer, and Phil Lee, our Chief Financial Officer. Before we begin, I would like to remind everyone that during this conference call, VaxArt may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials. Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, and other risks described in the Risk Factors section of VaxArt's most recently filed annual report on Form 10-K, and also on other periodic reports filed with the SEC. VaxArt undertakes no obligation to update any forward-looking statements after the date of this call. I'll now turn the call over to Andre Gloria.
spk03: Andre. Thank you, Brent, and thank you to all of you for joining us today. On today's call, we will highlight the recent progress we have made on our norovirus oral pill vaccine program. We will also look ahead to our remaining planned milestones for the second half of the year and briefly discuss our COVID program before opening the call to your questions. During the second quarter, we are pleased to report positive preliminary top-line results from our Phase II dose-ranging study for our bivalent norovirus oral vaccine candidates within our stated timeline. James will provide a review of that data and what it means for this potentially groundbreaking vaccine. It is important to point out that this data builds on the growing body of evidence that validates Vaxart's platform to explore the potential advantages of mucosal vaccination. All our vaccines are designed to trigger mucosal immunity, and this is a very important distinctive feature of our platform. The clinical data we have generated thus far across our multiple programs suggests that mucosal vaccination could provide several important advantages. Broader cross-variant protection, reduction in viral transmission, more durable protection, and a broader immune response through the activation of both serum and mucosal immunity. The other important distinctive feature of our vaccines is the oral pill format. The potential advantages of oral pill vaccines are so fundamental that making them a reality could radically change how we think about vaccines and vaccination globally. Oral pill vaccines would allow us to vaccinate a lot more people faster, more easily, and painlessly than we are doing today with injectable vaccines. This vision is the future of vaccination that we are working so hard to achieve. Across FACTSAR, we are excited about the potential of our norovirus vaccine program. We believe we have the most advanced norovirus vaccine candidate in clinical development that is both formulated for oral administration and designed for delivery to the gastrointestinal system. Norovirus is a significant public health issue in developed countries, and there is no approved vaccine. More than 21 million people are infected in the U.S. each year, resulting in an annual disease burden of more than $10 billion in the U.S. alone. And the virus continues to be a leading subject of infectious disease stories across the country this summer, as the number of cases has spiked to at least a three-year high. We believe our Norovirus vaccine program has the potential to address this need and the significant, tremendous disease burden that Norovirus carries. Looking ahead, we have two important clinical milestones this year, and we remain on track to achieve them both. First, we anticipate reporting top-line data from the ongoing face-to-challenge study of our G11 norovirus vaccine candidates in the third quarter of this year. And then, we look forward to initiating this year the Bill and Melinda Gates Foundation-funded clinical trial to evaluate the ability of our norovirus vaccine candidates to induce antibodies in breast milk and transfer of antibodies to young infants. Before I turn the call over to James, I want to provide a brief update on our COVID program. To date, Vaxar's COVID-19 vaccine constructs have demonstrated a favorable immune profile. Vaxar continues to make progress on this program. And we believe, based on the new causal cross-reactivity data we have seen in our current constraints, that there may be a pathway to develop an oral pan-beta coronavirus vaccine. We are assessing next steps and will provide updates as they become available. Recently, the White House announced a new Office of Pandemic Preparedness and Response Policy. We are very encouraged by the US government's proactive approach to pandemic preparedness and strongly support global efforts to get ahead of the next global health crisis. As we cope with the post-emergency phase of the pandemic, we must build stronger defenses against future infectious diseases and other threats we will face. VaxHealth believes a cross-protective vaccine could improve our ability to fight future pandemics and is committed to that effort. As you can see, we strongly believe in the potential of our technology and what it could mean for global public health and are excited for the opportunities that lie before us. Now, I'll turn the call over to James for a more detailed review of our Norovirus program. Thanks, Andre.
spk08: We made significant clinical progress in the second quarter, highlighted by the positive preliminary top-line data that we reported from the phase two dose ranging study for our bivalent norovirus vaccine candidate. We believe these data we have seen to date show promise for this vaccine candidate, and more broadly, our vaccine platform. Recall that this candidate contains two genotypes, G11 and G24, both of which have caused the majority of norovirus disease in humans over the past 20 years. As a reminder, this study enrolled 135 healthy adults at three sites in the United States. The first 10 Sentinel subjects received open-label high-dose vaccine, and the remaining subjects were randomized to high- or low-dose vaccine or placebo. Each of the double-blinded vaccine arms had 50 subjects, and the placebo arm had 25 subjects. The primary endpoints were safety, and immunogenicity in order to determine a dose level for phase three development. Now, let's take a moment to review the results. As we described in detail in our July announcement, the preliminary results of the trial showed robust serum immune responses across all doses at day 29 relative to day one. Both vaccine doses showed a similar increase in serum antibody responses with no statistical difference between the medium and high-dose arms. At day 29, increases in serum IgA, serum IgG, and BT50 for both the G24 and G11 strains in the vaccine arms were similar to those seen in previous norovirus studies conducted by Vaxart. The results also demonstrate that the bivalent norovirus vaccine candidate was well tolerated with a favorable safety profile that included no vaccine-related serious adverse events or SAEs and no dose-limiting toxicity. Adverse event rates for both doses were similar to placebo. I'd like to point out that the preliminary data were for serum responses. Mucosal and cell-based assay data will be available at a later date. The totality of the data from this bivalent study and the data we expect from our ongoing norovirus challenge study will help inform our selection of dosage levels in a larger Phase IIb study and could support an end of Phase II meeting with the US FDA, potentially in 2024. I'll now turn to the Phase II G11 norovirus challenge study, which is measuring the safety immunogenicity, and efficacy of our monovalent norovirus vaccine candidate. This study may also help identify a correlate of protection between immune responses to the vaccine and a reduction in the risk of norovirus infection and or acute gastroenteritis secondary to norovirus. Enrollment in this ongoing double-blinded study is now completed, and we continue to expect to unblind the study and report top-line data during the current third quarter of 2023. We continue to believe in the potential of our bivalent norovirus candidate as we proceed toward a BLA submission. We look forward to updating you on our progress in the coming months. I'll now hand the call over to Phil Lee, our CFO, for a brief discussion of our financials.
spk00: Phil? Thanks, James. The details of our financial results for the second quarter of 2023 are summarized in today's press release. Revenue for the second quarter of 2023 was $1.4 million compared to no revenue in the second quarter of 2022. Revenue in the second quarter of 2023 was primarily from revenue recognized for work performed under VaxArt's grant from the Bill and Melinda Gates Foundation. Vaxar ended the second quarter of 2023 with cash, cash equivalents, restricted cash, and marketable securities of $67.9 million, compared to $71.8 million as of March 31, 2023. The decrease was primarily due to cash used in operations as we advanced our Norovirus program, which was partially offset by $13.6 million of net proceeds from a public offering completed in June 2023. The offering extends the company's expected cash runway into the third quarter of 2024. On behalf of all of us at Vaxart, I'd like to thank you for your time today. We will now open the call for your questions.
spk05: Thank you. At this time, we'll be conducting a question and answer session. If you'd like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. My first question comes from Charles Duncan with Cantor Fitzgerald. Please proceed with your question.
spk07: Hi, Andre and team. Congratulations on the quarterly progress. So, you know, earlier this quarter, you announced a preliminary top-line data from the Phase 2 dose-ranging study for the bivalent norovirus vaccine candidate that you touched on during the prepared remarks. You know, when you look at the immunogenicity data generated by the study, And you compare it to responses observed, let's say, after a natural infection to either strain. You know, how do you feel about the response? And does the data suggest that, you know, you need to go lower or higher in dose? Or do you believe you have the right dose in hand?
spk08: I'll take that one. Thanks. So, you know, we're fairly pleased that the data from that study to date is consistent with previous norovirus study results. You recall the preliminary top-line data we announced in July, we showed robust serum immune responses across all doses at day 29 relative to 21. The mucosal and the cell-based assay data, that's pending, and that will be available at a later date. Once we've assessed that data, I think we can make a stronger decision moving forward.
spk07: All right, James, thanks. And also, what are your thoughts on a one-dose regimen versus a two-dose regimen for this program?
spk08: I think for adults at one does regimen Right.
spk07: And, you know, as we move into three Q, you know, we're anticipating seeing data from the number of Irish town study, you know, just wondering, you know, if you can sort of lay out Oh, what you would like to see perhaps from a qualitative perspective, rather than quantitative know that you would find encouraging and would like to take to the agency for the end of phase two meeting.
spk08: I don't want to project the data results before we have them. Certainly if we stay on track with what we've seen in previous studies and note robust responses from mucosal or cell-based assays, that would be very encouraging. And then also we're looking forward to the data that we should announce later in Q3 of this year in terms of the Neuro G11 challenge. So that will be inclusive of that for a decision to be made as well.
spk07: Okay. And there's the last question, you know, sort of, you know, again, I know that you have to have your end of phase two meeting, you know, but when do you sort of anticipate or expect to operationalize the next study? And do you see Baxar driving the program alone forward or you have thoughts of bringing in a partner?
spk08: I'll take the first half and then pass the second half off to Andre, if that's okay. I think that from my standpoint, again, we'd like to see the data from this study as well as the 201 challenge study before going to the FDA. You know, the second portion of a study, a larger study, would then lead us to, Phase IIb would lead us to the end of Phase II discussions with the FDA. And as I mentioned before, that could be as soon as 2024. Andre, do you want to comment on the second section of that question?
spk03: Sure. So, Steve, you know, As our closest competitor in the norovirus space, Kilovax, has noted earlier this year, late-stage vaccine assets such as the norovirus programs are of interest to many large pharma and medium-sized pharma and will obviously entertain those discussions once we have the data. And as you can appreciate, there are and disadvantages to partnering and doing it alone. And we are open to evaluating the options and decide which ones will maximize value and bring the vaccine sooner to patients.
spk07: All right. I look forward to the challenge study data. And thank you for taking our questions.
spk05: Our next question comes from Mayak Mantani with B. Reilly Securities. Please proceed with your question.
spk04: Good afternoon, team. Thanks for taking our questions and congrats on the progress. So just for the monovalent challenge study, kind of your execution and enrollment has gone, you know, from what I can tell, faster than your original expectations. So could you just comment on that? you know, the learnings you may have executing on the study and, you know, time of the year, you know, when you get these infections and, you know, how could you apply some of this to, you know, additional, obviously, maybe challenge study work you may have to do with your bivalent or maybe at some point execute on the e-study in neurovirus. So we'd love to hear some commentary around that. And then, on the, uh, uh, mucosal data that you may look to report, uh, incremental to your dose ranging, uh, biovalent data that you already presented in the data. Could you just remind us what you had seen previously, um, uh, with, with your prior construct so that, you know, we are able to kind of bracket, uh, some, uh, scenarios here for what we may see on IDA and, um, And when would you look to kind of present that? Is there a medical conference you're targeting? And then I have a financial question and follow-up.
spk08: Yeah, thanks, Mike. So I'll take the first portion. I may have Sean Tucker, our CSO, chime in on the mucosal immunity as he is a world expert in mucosal immunity. So in terms of the learnings from the channel study, recall that channel studies typically They're much more aggressive than what you'd see in nature in the real world. The sample size for this study was built primarily for descriptive statistical analysis, as we're looking to understand really the mechanics of how this vaccine works. And to do this, we have a number of measures we're looking at, including a decrease in the severity of acute gastroenteritis caused by norovirus, a decrease in viral shedding, what our vaccine's impact or effect could be on infectivity, And then the effect on disease severity. So these are all things I think that from a clinical or global health standpoint are very important. Along with that, we're looking at safety and immunogenicity and the potential for taking a look at what a correlate of immunity might be. For those on the call and listening in, norovirus gastroenteritis is traditionally thought to be more seasonal in presentation. So you certainly have more norovirus by and large for seasonal distribution in the winter months. That said, there are outbreaks of norovirus that continue really on any month of the year. One only has to take a look at the CDC website here in the United States or the WHO's very robust database or the New York Times to take a look at when outbreaks occur either in nursing homes or in cruise lines, et cetera. So I think that there is some seasonality to the traditional spread of norovirus, but it is a viral infection that impacts people year-round. And because of that, I think that we'll take a look at executing challenges in the future, should they be needed, both when the challenge model is available, and we think that we have the best opportunity to recruit individuals to move forward in the study. As you mentioned, we're very fortunate to move this study forward and to be able to deliver the data on time, so we're very excited about that. For the mucosal immunity question, you asked specifically in terms of the, I think, what we're looking at in terms of the mucosal immunity for the 202 study. And for the 202 study, we don't yet have that mucosal immunity. That would be upcoming, right? And for the historical mucosal immunity, I'd ask Dr. Sean Tucker if he'd like to just make a small comment on that as he ran that program at the time. Sean?
spk01: Sure. Yeah, it's a good question. So previously we've reported that we get a mucosal response around somewhere between 2 to 10 fold increases if you're looking at fecal or, you know, we even talked about nasal responses and you get a number of subjects that respond, you know, up to, you know, over 90% in terms of ASC count or in terms of, you know, the nasal response, you know, if you look at it really carefully. So our expectation is that the G11 will see a similar mucosal response as well.
spk04: Got it. Appreciate the helpful, comprehensive answer there. So just on the financial runway kind of extension that you guided to 3Q next year, could you clarify how much incremental non-diluted funding you're baking in there, be it from Melinda Gates Foundation or even the, you know, any other forms of government funding?
spk03: You want to take this?
spk00: Sure. So I think in terms of our extended runway guidance, you know, it's really based on our current plans and our existing grant from the Gates Foundation, right? So we, again, once we see the data from the 201 study and really determine the path forward for the study, then we'll kind of determine the next steps and incremental spend as needed. But for now, it's all based on our existing plans and existing grant and no new grants at this time.
spk04: Okay, got it. Thanks, team, for taking our questions and look forward to the data shortly here from the challenge study.
spk03: Thank you, Mike.
spk05: As a reminder, if you'd like to ask a question, please press star 1 on your telephone keypad. One moment while we poll for questions. Our next question comes from Roger Song with Jefferies. Please proceed with your question.
spk02: Good afternoon. This is Liang Cheng on Roger Song. Thank you for taking our question. Our first question is about the upcoming phase 2 challenging data. Could you give us some color on what would be the go, no-go decisions for the Phase II challenging data?
spk08: I can give you some color. As opposed to go, no-go, I think we'd have to talk as a team, but certainly we're looking at several endpoints and indicators. So looking at a decrease in severity of acute gastroenteritis. I mentioned before that a challenge study is a is very aggressive compared to what someone sees in nature. So we're trying to ensure that those who could get sick would get sick, right? But we're looking for a decrease in severity of acute gastroenteritis secondary to norovirus, potentially a decrease in shedding. And I think that shedding is important because that could then be, you know, somewhat of a surrogate for decreasing shedding. You would decrease transmission, or you may. Effect on infectivity, I think, is going to be very important. And again, I tie that to viral shedding And then disease severity, right? So how ill are people actually getting? I think we're looking at all of those items along with the immunogenicity and the safety, but also trying to tease out, if we can, what a correlative immunity might look like. And I think those are the things that we're considering as we look at that data set.
spk02: Sure. Thank you. This is very helpful. In terms for the larger Phase IIb study, do we have any guidance, and could you provide some colors on the study design?
spk08: Sure. So I can give you some thoughts. You know, we would look at the evidence we see or the data that we are seeing from both the 202 study that we're talking about, some of that data in hand now, but waiting on the mucosal data, as well as the impact of the data we see from the 201 challenge study. And taking a look at both of those, I think we'll be able to determine or help determine what the size of the study might look like. You know, one of those factors that may impact it is if we are able to determine a correlate, right? Having a correlate in hand would mean decreasing the size of, if not the phase two, certainly the phase three. So phase two of the study would be larger. You need to have enough people enrolled to ensure that you have a safety set that would be acceptable to the FDA. I don't necessarily want to speak with the FDA, but certainly it would be larger than the study we had done now. And we would be, you know, ready to execute once we have those data in hand and have met internally. I hope that answers your question.
spk02: That is great. Thank you. Maybe a quick one for last. So in terms for the pivotal phase three, I know that probably you don't have much information. So what age populations would be prioritized? If you can comment on that.
spk08: Sure. I'll speak specifically to that question or generally about the phase three, right? Again, that phase three would depend on the results of the G11 challenge study, the phase two 2B study, At the end of phase two meeting with the FDA, we take the guidance of the agency literally to heart as we're all, I think, interested in providing a solution for what is now unanswered, which is there's no approved vaccine for norovirus, right? I think that we'd address the timing for the phase three once we have more visibility informed by those milestones. In terms of where we're at right now, you know, we have tested in this study the vaccine 18 and older, and I think that's what we're looking for as we march forward. But that would be dependent. The phase three design would be dependent on conversations with the agency, the FDA.
spk02: Thank you. I think that's all from us. Thanks.
spk05: There are no further audio questions at this time. I'd like to turn the call back over to your host, Brant Behan.
spk06: Thanks very much. So we had a lot of questions that had been sent in previously ahead of time on various channels. I think most of those have now been asked between Charles and Meg. So here's one that I don't think has been answered completely yet. James, this one's coming to you. Do you see any accelerated path to commercialization, such as an EUA or a smaller Phase III study for norovirus, and what's a realistic timeline to commercialization? James.
spk08: Fair enough. Thanks, Brent. So, you know, we continue to address the potential options and the timing for commercialization. Once we have more visibility informed by these study results that we're just discussing now, based on those results, those data, and interactions with regulatory agencies, will determine the best plan and timeline for commercialization.
spk06: That's fantastic, James. Thanks. And another one I don't think we hit on during the call, and James, it's also going to be for you. Please remind us what you're looking for in the infant study and potential implications for your norovirus program.
spk03: James.
spk06: Sure.
spk08: Thank you. So, you know, it's unknown how norovirus infectivity and spread would be impacted or affected by a vaccine. As I mentioned, there's no currently approved vaccine against norovirus. However, there are some studies that suggest that if you vaccinate children, you can also improve the health of adults. You might not be able to protect against all illness, but we know that children acquire disease and can infect their families. So that's one of the pieces we're looking at.
spk06: Fantastic. Thanks, James. So that's the majority of the other Norovirus questions have been asked already and answered by you. So thank you so much for that. I think investors and people on the line that have further questions can take a look at our Fireside chat platform on the investor section of our website and can go ahead and post additional questions. And we'll follow up at a Fireside chat meeting in the near future and answer those questions. So at this point, we'll close the meeting. Thank you.
spk05: This concludes today's conference and webcast. You may disconnect your lines at this time, and we thank you for your participation.
Disclaimer